Literature DB >> 10980211

Relation between coronary atherosclerotic plaque burden and cardiac enzyme elevation following percutaneous coronary intervention.

P K Kanaparti1, D L Brown.   

Abstract

Several studies have reported that elevation of cardiac creatine kinase (CK) enzymes after percutaneous coronary intervention (PCI) is associated with an increase in cardiac morbidity and mortality during follow-up. However, it remains unclear if enzyme elevation contributes to the adverse outcomes or is simply a marker for adverse events. We conducted a case-control study to determine if angiographically determined atherosclerotic plaque burden correlated with CK elevation. Patients (cases, n = 23) with CK elevation after PCI were identified along with 46 age- and gender-matched controls without CK elevation. Detailed angiographic analysis quantified the percentage of coronary artery length with any luminal irregularity, a surrogate for plaque burden. The CK elevation group was characterized by a greater number of smokers (65% vs 33%, p = 0.02), more thrombus-containing lesions (22% vs 2.2%, p = 0.014), and more frequent abrupt closure (13% vs 0%, p = 0.03). In addition, the case group had a 50% increase in atherosclerotic plaque burden compared with controls (30 +/- 14% vs 20 +/- 14%, p = 0.006). These data suggest that CK elevation after PCI is a marker for more extensive atherosclerosis, which may explain the worse prognosis of these patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10980211     DOI: 10.1016/s0002-9149(00)01039-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

Review 1.  Redefining myocardial infarction for the 21st century.

Authors:  Joseph S Alpert; Beth R Malasky; Kristian Thygesen
Journal:  Trans Am Clin Climatol Assoc       Date:  2004

2.  Temporal changes in circulating P-selectin, plasminogen activator inhibitor-1, magnesium, and creatine kinase after percutaneous coronary intervention.

Authors:  Shu-qin Ying; Mei-xiang Xiang; Lu Fang; Jian-an Wang
Journal:  J Zhejiang Univ Sci B       Date:  2010-08       Impact factor: 3.066

3.  Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions.

Authors:  Oyku Gulmez; Aylin Yildirir; Gamze Kaynar; Didem Konas; Alp Aydinalp; Cagatay Ertan; Bulent Ozin; Haldun Muderrisoglu
Journal:  J Thromb Thrombolysis       Date:  2007-06-16       Impact factor: 2.300

4.  Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI).

Authors:  Issam D Moussa; Lloyd W Klein; Binita Shah; Roxana Mehran; Michael J Mack; Emmanouil S Brilakis; John P Reilly; Gilbert Zoghbi; Elizabeth Holper; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2013-10-22       Impact factor: 24.094

5.  Circulating soluble lectin-like oxidized low-density lipoprotein receptor-1 levels predict percutaneous coronary intervention-related periprocedural myocardial infarction in stable patients undergoing elective native single-vessel PCI.

Authors:  Mehmet Balin; Ahmet Celik; M Ali Kobat; Adil Baydas
Journal:  J Thromb Thrombolysis       Date:  2012-11       Impact factor: 2.300

6.  Incidence and impact on prognosis of peri-procedural myocardial infarction in 2760 elective patients with stable angina pectoris in a historical prospective follow-up study.

Authors:  Martin Kirk Christensen; Hui Huang; Christian Torp-Pedersen; Torleif Trydal; Jan Ravkilde
Journal:  BMC Cardiovasc Disord       Date:  2016-06-16       Impact factor: 2.298

7.  Impact of periprocedural myocardial injury on long-term clinical outcomes of chronic total occlusion patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Authors:  Mei-Jun Liu; Chao-Feng Chen; Xiao-Fei Gao; Xiao-Hua Liu; Yi-Zhou Xu
Journal:  Coron Artery Dis       Date:  2020-05       Impact factor: 1.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.